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Aged keratinocytes have diminished proliferative capacity and hyaluronan (HA) cell coats, which are losses that contribute to
atrophic skin characterized by reduced barrier and repair functions. We formulated HA-phospholipid (phosphatidylethanolamine,
HA-PE) polymers that form pericellular coats around cultured dermal fibroblasts independently of CD44 or RHAMM display. We
investigated the ability of these HA-PE polymers to penetrate into aged mouse skin and restore epidermal function in vivo. Topically
applied Alexa647 -HA-PE penetrated into the epidermis and dermis, where it associated with both keratinocytes and fibroblasts. In
contrast, Alexa647 -HA was largely retained in the outer cornified layer of the epidermis and quantification of fluorescence confirmed
that significantly more Alexa647 -HA-PE penetrated into and was retained within the epidermis than Alexa647 -HA. Multiple topical
applications of HA-PE to shaved mouse skin significantly stimulated basal keratinocyte proliferation and epidermal thickness
compared to HA or vehicle cream alone. HA-PE had no detectable effect on keratinocyte differentiation and did not promote
local or systemic inflammation. These effects of HA-PE polymers are similar to those reported for endogenous epidermal HA in
youthful skin and show that topical application of HA-PE polymers can restore some of the impaired functions of aged epidermis.

1. Introduction
Hyaluronan (HA) is a ubiquitous extracellular matrix tissue
polysaccharide belonging to the glycosaminoglycan family,
which is characterized by repeating hexosamines and uronic
acid [1–3]. Skin HA accounts for approximately 50% of total
body HA and occurs in both the epidermal, and dermal
layers. Here it performs a variety of functions that are related
to its rheological, viscoelastic and biological properties [4–
6]. For example, its rheological properties contribute to the
overall quality, hydration, permeability, and immune barrier
functions of skin while its unique viscoelastic properties protect skin cells from mechanical damage [7–11]. The biological
properties of HA include a contribution to cell survival,

proliferation, and migration, and result from its ability to
activate key signaling cascades through interactions with
cellular HA receptors, which in keratinocytes is primarily
CD44 [12–18]. HA is also an important regulator of skin
immune surveillance [19] and response to injury processes
[15, 20–25]. Although the primary structure of HA is simple and is composed only of linear repeating N-acetyl-Dglucosamine and glucuronic acid disaccharides, its functions
are complexly regulated and dependent upon its organization
by extracellular and cellular proteins as well as by polymer
size [14, 16, 21, 23].
The organization of HA in the extracellular matrix and
around cells is a critical component of its skin functions
[6, 26, 27]. On keratinocytes, HA is structured as compact
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pericellular coats that are maintained by CD44. Dermal HA
is more abundantly extracellular and linked to a variety
of proteoglycans including versican [28–34]. The cellular
and extracellular organization of skin HA is critical for its
retention in the papillary dermal and keratinocyte layers.
Quantitative loss of HA from these layers is associated with
skin pathologies including poor wound healing, reduced skin
elasticity/mobility, and loss of keratinocyte tight-junctions
and permeability barrier functions [4, 27, 29, 35–44]. Polymer
size also contributes to the skin functions of HA. For example,
high molecular weight (HMW), native HA in skin protects
against tumor initiation [45], provides intrinsic water binding
properties of skin [26] and is required for dendritic cell
functions [15, 19, 46]. It regulates the proliferation and differentiation of the basal keratinocyte layer during homeostasis
and response to injury [4, 6, 47, 48] and contributes to the
barrier/hydration function [26, 34, 49] and structure of the
stratum corneum [50].
Most HA in homeostatic skin is high molecular weight
but fragmentation occurs following injury or prolonged
exposure to UV. In cooperation with the fragmentation of
other extracellular matrix components, HA fragments activate signaling cascades in keratinocytes and dermal fibroblasts that control migration, survival, and redifferentiation
required for repair of injured skin [51–58]. HA fragments are
also key regulators of innate immunity and are required for
in-trafficking and proinflammatory cytokine expression of
macrophages [15, 19]. The different functional effects of native
versus fragmented HA likely result from selective interactions
with specific receptors and differential effects of polymer size
on the clustering/signal activation through these receptors
[13, 15, 59]. The effects of native HA on homeostatic keratinocyte functions are mediated through CD44 [4, 30] while
repair functions of HA fragments involve coordination of
signaling through CD44 : RHAMM and TLR2, 4 complexes
[55, 60, 61].
Chronological skin aging results in physiological alterations of keratinocytes and epidermal functions that contribute to epidermal thinning or atrophy, and barrier dysfunction, delayed wound repair, as well as increased susceptibility to pathologies including ulceration, dermatitis, and
eczema [4, 60, 62]. Although age-associated epidermal dysfunction is not well understood, it is associated with changes
in HA concentration and organization, and CD44 display
[4, 63]. Experimental models have established that reduction
or loss of keratinocyte CD44 results in epidermal changes that
are similar to aging dysfunction such as thinning of the epidermal layer, barrier dysfunction, modified HA metabolism,
reduced HA production, altered keratinocyte differentiation,
and decreased skin elasticity. Application of HA to aged
mouse skin partially restores permeability barrier homeostasis and epidermal thickness [41, 42]. Topical or injected
HMW HA products have had variable effects in restoring
a sustained physiological and hydrated microenvironment
of youthful skin required for optimizing tissue repair and
rejuvenation [4, 62, 64, 65]. Transepidermal or dermal HA
delivery modalities, although promising, have similarly failed
to reliably replenish sustained high levels of native HMW HA
in the epidermis or dermis of aged skin [66–68]. This failure
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is likely because of poor penetration of topically applied
HA formulations of MW greater than 50 KDa [39, 69–71],
reduced HA capture in the epidermis as a result of declining
CD44 levels [4, 42, 72] and aberrant organization as well as
rapid clearance of the exogenous HA formulations [40, 60].
To address this problem, we developed a cell-based
screening method for identifying HA-phospholipid (phosphatidylethanolamine, HA-PE) formulations that form pericellular HA coats on fibroblasts and keratinocytes in a CD44independent manner [73]. We show that topical administration of HA-PE to the shaved skin of aged wild type or
CD44−/− mice increased HA within the epidermal layer. This
HA modification promoted basal keratinocyte and hair follicle proliferation as well as increased epidermal thickness but
does not detectably alter the differentiation of keratinocytes.
In addition, topical application of HA-PE in vivo did not
result in either a local or a systemic inflammatory response.

2. Methods
2.1. Animals. Forty-five retired breeder ten-month old female
C57BL/6 mice (Jackson Laboratory) were used for the multiple cream application studies. An additional twelve retired
breeder twelve-month old female C57BL/6 mice were used
for the Alexa647 mouse experiments.
Animals were individually caged in a temperaturecontrolled environment with a 12 h light/dark cycle and fed
a standard mouse chow diet. All experiments were approved
by and compliant with the standard operating protocols of
the Animal Use Subcommittee at the University of Western
Ontario, Canada (2009-051).
2.2. Preparation of HA-PE and HA. For preparation of the
HA-PE cream (Patent identification: WO2011140630 A1) [74],
1.35 mL of unrefined liquid soy lecithin (Soy Lecithin GT
non-GM IP, Imperial-Oel-Import, Germany) was mixed
thoroughly at room temperature with 1.35 mL of 1% v/w
Sodium Hyaluronate Solution (500 kDa, Medical Grade,
Lifecore Biomedical, Chaska, MN, USA) and 252 𝜇L of
isopropanolol. Subsequently, 3.78 mg of dry 1-ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC) was added and
mixed thoroughly as a linking agent. After mixing for 10–
15 minutes, 3 mL of vehicle cream was added and mixed for
another 5 minutes. For preparation of unmodified HA cream,
1.35 mL of 1% v/w Sodium Hyaluronate Solution was mixed
thoroughly with 3 mL of vehicle cream.
A water-based cream (Mango Face cream, Aquatech,
Toronto) was used throughout the study as the vehicle for
mixing with unmodified HA or HA-PE. Formulated creams
were stored protected from light at 4∘ C.
2.3. HA Pericellular Coat Detection. HA pericellular coats
were detected using particle exclusion [75]. Dermal wild type,
CD44−/−, RHAMM−/−, and CD44 : RHAMM−/− embryonic fibroblasts were plated onto 35 mm tissue culture dishes
in DMEM + 10% FBS for 24 hrs. Cells were then fixed in 2.5%
glutaraldehyde in 0.1 M cacodylate buffer, 5 mM CaCl2 , pH
7.2, for 30 min then washed gently in cacodylate buffer. 1 mL
of either FITC-labeled 0.4 mm microspheres (Invitrogen) or
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formalized sheep erythrocytes (1 × 108 erythrocytes/mL) was
added to each 35 mm culture dish and swirled gently so that
cells were evenly covered. Dishes were incubated for 15–
30 min at 37∘ C to let beads or erythrocytes settle around
cells. As a control, cells were incubated with 200 𝜇g/mL
bovine testicular hyaluronidase (Sigma) for 1 h at 37∘ C prior
to performing the particle exclusion assay. Cells were then
photographed with a Nikon inverted microscope equipped
with epifluorescence and Hoffmann optics.
2.4. Preparation of A647 -HA. In the preparation of A647 HA, the solution was protected from ambient light. In
a laminar flow hood, 0.0028 g of EDC (Sigma Aldrich,
http://www.sigmaaldrich.com/) was dissolved in a 1 mL solution of 20 mM MES and 30% ethyl alcohol (pH 4.5) in a 15 mL
tube. Subsequently, 200 𝜇L of pharmaceutical grade 1% v/w
Sodium Hyaluronate Solution (500 kDa) (Lifecore Biomedical, Chaska, MN, USA) was added. After five minutes, 300 𝜇L
of Alexa Fluor 647 Hydrazide, Tris (triethylammonium) salt
(Life Technologies, http://www.lifetechnologies.com/) was
added. The A647 -HA solution was placed on a rocker at room
temperature for 12 hours and then dialyzed (10,000 dalton cut
off, Thermoscientific) at 4∘ C. The entire volume of 1X PBS
buffer was exchanged at 1, 3, and 5 days. The retained A647 -HA
solution was retrieved from the dialysis apparatus and stored
in a 15 mL tube in the 4∘ C fridge.
2.5. Application of A647 -HA/HA-PE to Mice. Mice were anesthetized using Isofluorane gas for application of cream. While
anesthetized, the upper dorsum of the back was shaved with
an electric razor, leaving a strip of hair in midline to define
the right and left sides. 0.18 g of A647 -HA and A647 -HA-PE
cream was applied to the left and right sides, respectively. Two
mice were euthanized using a CO2 chamber at each of six time
points: 40 min, 2 h, 4 h, 8 h, 24 h, and 72 h following cream
application.
2.6. Preparation and Analysis of A647 -HA-PE. A full-thickness biopsy of the A647 -HA/HA-PE treated area was obtained
and lightly fixed for 10 minutes in 1.5% paraformaldehyde containing 0.5% cetylpyridinium chloride monohydrate
[75] in PBS. Each specimen was subsequently fixed in 4%
paraformaldehyde (pH 7.4) for an additional 30 min then
stored at −4∘ C. Tissue samples were paraffin processed,
mounted then analyzed with a Nikon Eclipse motorized
upright microscope. The penetration of A647 -HA/HA-PE into
the epidermis was quantified using Image J, which converted
fluorescent images to pixel density per a tissue area. A total
of twelve C57BL/6 retired breeder female mice were used for
this experiment.
2.7. Treatment of Mice with HA-PE. Three treatment arms
were used for these experiments: HA-PE cream, HA cream,
and vehicle cream and 15 mice were used per group. For
the initial cream application, mice were anesthetized, shaved,
and treated as described above. Subsequent once daily cream
applications were performed without anesthesia. Five mice
in each treatment arm were sacrificed after one, five, and ten
applications. At each of these times, mice were euthanized, a
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blood sample via a cardiac puncture and two four-millimeter
punch skin biopsies was obtained. The remainder of the
shaven treatment area was excised and stored at −80∘ C.
To provide a positive control for inflammation markers, an
additional mouse was wounded with a 4 mm punch biopsy
as described previously [76], then tissue harvested using an
8 mm punch biopsy 3 days after wounding. All tissue biopsies
were fixed in 4% paraformaldehyde/PBS at 4∘ C for 24 h. Samples were then processed for paraffin histology sections. For
immunohistochemistry, tissue sections were deparaffinized
and antigen retrieval was performed by heating tissue sections in a microwave oven in 0.01 M aqueous sodium citrate
buffer (pH 6.0). Tissue sections were washed then incubated
with one of the following primary antibodies: rabbit Ki67
monoclonal (1 : 100 Abcam), rabbit K10 monoclonal (1 : 7000
dilution, Abcam), and rat F4/80 monoclonal (1 : 100 dilution,
AbD Serotec) followed by the appropriate biotinylated secondary antibody. Sections were counterstained with hematoxylin then mounted in Richard-Allan Scientific Cytoseal 60
(ThermoScientific). Digital images of stained tissue sections
were obtained using an Aperio Scanscope. Five representative
areas were taken per mouse and analyzed using Image J.
2.8. Measurement of Epidermal Thickness. To evaluate epidermal thickness, the above tissue sections stained with hematoxylin and eosin (4X magnification images) were analyzed
using Image J. For each mouse, fifty serial measurements at
75 um intervals per section were made to determine epidermal thickness (stratum basale to the stratum granulosum)
[77].
2.9. TNF-𝛼 ELISA. Activated macrophages and proinflammatory cytokines, such as TNF𝛼, appear to be ubiquitous
players in cutaneous inflammation regardless of the inciting
stimulus whether wounding or sterile inflammation [78–80].
Dissected tissue samples from each of treatment and group
and wounded tissue were mixed gently RIPA lysis buffer
and a protease inhibitor tablet for 10 min and then sonicated
for three 20-second pulses. Samples were incubated on a
rotary shaker at 4∘ C in lysis buffer for an additional 45 min
then centrifuged at 13,000 g (4∘ C) for 30 min. The pellet was
discarded and supernatant used for the TNF𝛼-ELISA assays
(Abcam), which were performed per the manufacturers
instructions. Triplicate samples of 100 𝜇L of each were used
for these assays.
2.10. C-Reactive Protein ELISA. Serum was obtained from
blood harvested via cardiac puncture. The serum samples
were centrifuged at 3000 rpm at 4∘ C for 10 mins using an
Eppendorf Centrifuge and stored at −80∘ C until analysis.
Samples were analyzed for the presence of C-reactive protein
using an ELISA kit (Abcam) and assays were performed using
the manufacturers instructions. Triplicate samples (100 𝜇L) of
each sample were used for these assays.
2.11. Statistical Analysis. One Way ANOVA and Tukey test,
as a post hoc analysis, were used to determine statistical
significance between groups using a 𝑃 value of 0.05. Data are
expressed as mean ± standard error of the mean (S.E.M) of at
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least five independent samples as described above. Statistical
analysis was performed using GraphPad Prism 6 (GraphPad
software).

3. Results
3.1. Formulating and Characterizing HA-PE Polymers That
Form Pericellular Coats. Using a cell-based screen, HA-PE
polymer formulations were prepared. The polymer formulations that formed nanoparticles were discarded while those
that were nonparticulate and formed pericellular coats on
fibroblasts were identified using particle exclusion assays
(Figure 1(a)). Addition of HA-PE polymer resulted in a significant increase in the number of cells that formed pericellular
coats compared to those formed when PBS alone was added.
A light but significant increase in the number of cells forming
coats was also stimulated by exogenous unmodified HA of
the same size used for HA-PE formulations. Nevertheless,
the addition of HA-PE stimulated coat formation to a significantly greater extent than HA alone and a trend to formation
of larger coats was also observed (data not shown).
CD44 has been demonstrated to be critical for keratinocyte, fibroblast, and smooth muscle cell HA coat formation [32–34, 40, 42] and both CD44 and RHAMM [12, 14,
61] have recently been implicated in the binding of HA to
tumor cells and fibroblasts. The role of these HA receptors
in the formation of endogenous HA and HA-PE coats was
examined by comparing wild type primary mouse embryonic
fibroblasts (MEF) with those lacking RHAMM, CD44, or
both receptors due to genetic deletion of these genes (Figure
2(a)). Loss of RHAMM resulted in highly variable numbers
of MEF forming endogenous pericellular coats but these
were not significantly different from wild type fibroblasts.
Loss of CD44 however resulted in a 6-fold reduction in the
number of MEF exhibiting HA coats. Dual loss of CD44 and
RHAMM did not further reduce coat loss from that observed
in CD44−/− MEF. These results show that CD44 is the major
HA receptor that facilitates endogenous HA coat formation
in MEF consistent with previous studies of other cell types
including keratinocytes [33, 39, 42]. The effect of HA-PE on
RHAMM−/−, CD44−/−, RHAMM : CD44−/−, and wild type
MEF coat formation was compared next to begin to identify
the mechanisms for HA-PE-promoted pericellular HA coats.
As shown in Figure 2(b), the addition of HA-PE to these
different fibroblast genotypes resulted in a similar number
of cells with HA coats indicating that HA-PE effects were
not dependent upon HA receptor display including CD44,
which has previously been shown to mediate endogenous
coat formation (Figures 2(b) and 2(c)). However, HA-PE
stimulated coat formation in CD44−/− MEF was sensitive to
hyaluronidase as were endogenous coats (Figure 2(c)). These
results predict that addition of a PE group to HA promotes its
direct association with cells in a CD44-independent manner.
To determine if HA-PE promotes coat formation in other
cell types particularly in vivo, its effect on skin keratinocyte
HA pericellular coats, which have previously been shown
to require CD44 expression [30, 42] was next evaluated.
Adult mouse back skin was chosen for these studies since
it has been reported to produce very little endogenous
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HA [29], permitting more sensitive detection of exogenous
applications of HA-PE using staining methods to detect accumulated HA. Consistent with previous studies [29], very little
HA staining was observed in control (PBS) keratinocytes.
Topical application of HA-PE to wild type mice significantly
increased HA staining in the epidermis (Figure 3) but did
not detectably increase HA staining in the dermis when
compared to PBS-treated controls likely because the dermis
produces large amounts of HA and the staining method
was not sensitive enough to detect elevation above this
high background. These results show that HA-PE not only
enhances pericellular HA coat formation in cultured MEF
but also in epidermal keratinocytes in vivo. These results also
show that HA-PE crosses the outer cornified epidermal layer
more efficiently than unmodified HA.
The association of HA with keratinocytes in mouse skin
in vivo depends upon CD44 expression [30]. We therefore
next assessed if the loss of CD44 altered HA-PE mediated increases in keratinocyte associated HA in vivo. As
shown in Figure 3(b), topical application of HA-PE increased
hyaluronan staining of CD44−/− epidermis compared to PBS
controls suggesting that epidermal accumulation of HA-PE is
CD44 independent in vivo similar to cultured MEF. To more
directly follow the association of small amounts of HA-PE
with the epidermal and dermal skin layers, we labeled HAPE with Alexa-dye and analyzed its distribution after a single
topical application to mouse skin.
3.2. A647 -HA-PE Accumulates in the Epidermis and Penetrates
into the Dermal and Subdermal Skin Layers. A647 -HA-was
prepared, linked to PE (A647 -HA-PE) or not (A647 -HA) and
applied as equal amounts of HA to the shaved back skin
of mice as described in methods. Skin biopsy samples were
collected from 40 min to 72 h after the single application,
processed for histology, and examined with a confocal microscope. Confocal images showed accumulation of A647 -HAPE and particularly A647 -HA on the stratum corneum but
A647 -HA-PE also penetrated into the stratum granulosum as
well as the basal keratinocyte layers (Figure 4). Fluorescence
was also observed in dermal fibroblasts and even within the
subcutaneous muscle layer. Further analysis of the epidermis
revealed that A647 -HA-PE was most strongly associated with
subpopulations of basal keratinocytes and formed coats
around these cells (Figure 4, arrows). A647 -HA-PE also was
detected in fibroblasts of the upper dermis. In contrast, A647 HA primarily accumulated in the outer stratum corneum
with much smaller amounts penetrating into the epidermis
and dermis. In particular, A647 -HA accumulation was not
concentrated in the basal layer (Figure 4).
Since the boundary of the epidermal layer is clearly
identified, the amount of A647 -HA-PE in this layer was
quantified using image analysis as described in methods. For
these analyses, the fluorescent intensity of A647 -HA, A647 HAPE, and a negative control vehicle cream were compared from
the stratum basale to stratum granulosum layers of the epidermis. A647 -HA-PE penetrated into the epidermis as early
as 40 min after application and could be detected up to 72 h
after application (Figure 4). Accumulation of A647 -HA-PE
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Figure 1: HA-PE simulates pericellular coat formation in cultured fibroblasts. 500 kDa HA was linked to PE using EDC to achieve a
stoichiometry of 1 : 10 (HA : PE). (a) This ratio was selected because it resulted in the largest pericellular HA coats, which were detected
using fluorescent particle exclusion assays. (b) The black patches on the epifluorescent images are areas of pericellular coats. A Hofmann
image is included which shows cells at the center of the pericellular coats. Images were taken with a 10X objective. The percentage cells/10x
field that were surrounded by HA coats were calculated using Hofmann optics. (c) Values are Mean and S.E.M 𝑛 = 3 fields. Asterisks indicate
statistical significance (𝑃 < 0.01).

in skin was significantly greater than A647 -HA at all time
points but reached a maximum difference of 5 fold at 2 h. This
significantly elevated accumulation of A647 -HA-PE versus
A647 -HA was sustained for 24 h suggesting that HA-PE was
able to establish a stable organization within the epidermis.
Although A647 -HA-PE levels were still greater than A647 -HA
at 72 h after application, the difference did not reach statistical
significance (Figure 4).
Confocal analysis (24 h shown, Figure 4) showed that
A647 -HA primarily accumulated in the outer stratum corneum with little penetration into the dermis. A647 -HA-PE
was also present in the stratum corneum but unlike unmodified A647 -HA, accumulated around dermal fibroblasts. These
results show that HA-PE readily penetrates into and is
retained in the epidermal and deeper skin layers

The formation of pericellular HA coats have been linked
to cellular detachment during mitotic rounding of proliferating fibroblasts and smooth muscle cells [12, 16, 81]. HA
coats have also been linked to migration and differentiation
of keratinocytes in organotypic cultures [4, 13, 14, 30, 82, 83].
We therefore next assessed if increasing keratinocyte HA coat
formation by application of HA-PE affects the proliferation or
differentiation of this skin cell type.
3.3. HA-PE Increases Epidermis Thickness and Basal Keratinocyte Proliferation but Does Not Affect Keratinocyte Differentiation or Dermal Cell Proliferation. The consequence
of repeated HA-PE topical application on epidermal thickness was first quantified. As shown in Figure 5, daily topical application of HA-PE significantly enhanced epidermal
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Figure 2: Endogenous HA coats require expression of CD44 while HA-PE generated coats do not. The numbers of wild type and RHAMM−/−
fibroblasts that form endogenous HA coats are not significantly different. In contrast, loss of CD44 significantly reduces the numbers of
fibroblasts forming coats. This is not further reduced by loss of both CD44 and RHAMM. (a) However, loss of CD44 has no effect on the
number of cells forming coats as a result of HA-PE addition. (b) The pericellular coats formed by CD44−/− fibroblasts in the presence of
HA-PE are destroyed by hyaluronidase. (c) Images were taken with a 20X Hoffmann objective. Values are the Mean and S.E.M 𝑛 = 75 cells.

thickness by 24 h, 5 days, and 10 days after treatment initiation
when compared to application of unmodified HA or vehicle
control. Maximal epidermal thickness occurred between 24 h
and 5 days and was sustained throughout the treatment
period (Figure 5). The tissue samples were dehydrated prior
to analysis of epidermal thickness, and therefore values do
not account for any contribution of increased tissue hydration
from HA.
Consistent with this thickening effect on the epidermal
layer, topical application of HA-PE stimulated basal keratinocyte proliferation compared to unmodified HA or vehicle controls as detected by Ki67 staining, which is a cell
proliferation marker. In addition, increased Ki67 staining

of the suprabasal keratinocytes was observed in the HA-PE
group. The majority of epidermal proliferation and regeneration occurs by activation of stem cells in the basal layer of
the epidermis. The suprabasal levels contain transit-amplifying (TA) intermediate stem cells which are defined by a
finite number of cell divisions before entering a terminal differentiation pathway (85). The HA-PE cream appears to stimulate proliferation of both the basal layer and TA stem cells.
Increased keratinocyte proliferation was observed 1 day after
treatment initiation and was sustained throughout the treatment period, corresponding well with the time frame observed for the increase in epidermal thickness (Figure 6). Analysis of DAPI- and Ki67 stained skin sections 24 and 72 hr
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Figure 3: Topical application of HA-PE stimulates HA accumulation in wild type and CD44−/− keratinocytes in mouse skin in vivo. Topical
application of HA-PE to shaved B57/BL6 wild type mice increases HA in the keratinocyte layer as detected by biotinylated HABP (blue staining
indicates hyaluronan detected by HABP probe). (a) Staining 3 days after application is not detectably different in the dermis and although
patchy and variable in the epidermis is significantly different in HA-PE versus vehicle controls (brown staining indicates hyaluronan detected
by HABP probe) (𝑃 < 0.05). Images were taken with a 20X bright field objective. Similar results were obtained when the epidermal layer
was analyzed for hyaluronan after HA-PE was applied to B57/BL6 CD44−/− mice. Significantly greater HA staining was observed in HA-PE
treated versus vehicle controls (𝑃 < 0.0001). (b) Images were taken with a 10X brightfield objective. Values in (a) and (b) are the Mean and
S.E.M 𝑛 = 3 mice, 5 tissue section/mouse.

after application of HA-PE versus HA showed that dermal cell
number was similar in both treatments indicating that HAPE does not stimulate fibroblast or other dermal cell proliferation. This predicts that HA-PE effects on proliferation are
limited to the epidermal layer.
Growth factors such as keratinocyte growth factor (KGF)
that promote keratinocyte proliferation coincidentally inhibit
keratinocyte differentiation and hyaluronan production [84,
85]. We therefore next assessed if elevating HA around keratinocytes affects their differentiation cycle. The consequence
of HA-PE application on the expression of keratin-10 (K-10)
was quantified using immunohistochemistry. No detectable
effect of HA-PE application on K-10 staining was observed
suggesting that HA-PE does not modify keratinocyte differentiation (Figure 7).

keratinocyte proliferation, we next determined if topical
application of HA-PE affected local or systemic inflammation. F4/80 staining of skin tissue sections and TNF𝛼 was
used to identify localized activation of macrophages while
serum CRP levels were monitored to determine effects on
systemic inflammation. As shown in Figure 9, the application
of HA-PE did not increase F4/80 staining levels compared
to unmodified HA or vehicle controls (Figure 8). Furthermore, the levels of macrophage activation detected by this
method were very low compared to those detected in skin
wounds, which are known to contain high levels of activated
macrophages [87] and were used as a positive control.
Similarly local TNF𝛼 and systemic CRP inflammation levels
were not increased by topical application of HA-PE compared
to unmodified HA or vehicle controls (Figures 9(a) and 9(b)).

3.4. Topical Application of HA-PE Does Not Affect Local
Skin or Systemic Inflammation. Since HA and its fragments
are potent regulators of the immune system in particular
innate immunity [15, 19, 46, 86], which could indirectly affect

4. Discussion
Our results identify a method for preparing HA-phospholipid
(PE) polymers that do not require CD44 display for forming
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Figure 4: Topical A647 -HA-PE enters the epidermis. Significantly increased fluorescent staining of A647 -HA-PE is observed compared to
A647 -HA in the epidermis (stratum basale to stratum granulosum) at all time points up to 24 h (mean ± S.E.M, 20 skin images) (∗ 𝑃 < 0.05,
∗∗
𝑃 < 0.001) (right panel). Representative confocal images of A647 -HA-PE and A647 -HA treated mice sectioned at 24 h are shown. Merged
Dapi and Alexa647 staining are shown to indicate cellularity in tissue sections. The dashed line indicates the junction of the epidermis and
dermis. Arrowheads indicate areas of enhanced pericellular fluorescence. A647 -HA-PE and A647 -HA staining was pseudocolored green. Blue
staining is DAPI. An untreated adjacent skin section (no treatment) photographed using the Alexa647 channel is shown as a control for
autofluorescence.

pericellular coats around fibroblasts in culture and aged
keratinocytes in wild type and CD44−/− mice. These results
are consistent with a mechanism whereby HA-PE inserts
directly into the cell membrane via the phospholipid entity.
The topical applications of this HA-PE polymer increased
epidermal thickness of aged female mouse skin as a result of
stimulating the proliferation of the basal keratinocyte layer in
the absence of detectable dermal or systemic inflammation or
changes in keratinocyte differentiation rates.
Topical application of unmodified HA to intact skin in
situ penetrated into the epidermis and dermis as previously
reported [42, 69–71] but this was limited compared to HA-PE
polymers. In addition, most of the unmodified HA remained
associated with the stratum corneum and was not retained
in skin as long as HA-PE. The ability of unmodified HA to
penetrate the skin in small amounts, which can occur in
both rodent and human skin, is dependent upon molecular
weight. Thus, HA polymers smaller than 50,000 daltons
readily penetrate human skin ex vivo while larger HA chains
do not [69]. The average MW of HA used in the present
study was 500,000 Da and therefore the limited association of
unmodified HA with the epidermis is likely due to the polymer size restriction. The penetration of this HA size through
the outer stratum corneum is facilitated by the addition of

a phospholipid moiety and this addition likely increases solubility of HA in lipids (e.g., ceramides, cholesterol, and fatty
acids) [88] that are present in the stratum corneum. Retention
within the epidermis and dermis is likely promoted by the
ability of keratinocytes and fibroblasts to capture and retain
HA-PE as demonstrated in culture. Since HA-PE is able to
organize as a pericellular coat in the absence of CD44 display,
HA-PE polymers are able to spontaneously organize within
the epidermis and we predict that keratinocyte CD44 acts at
least in part as an anchor for attaching HA to outside of cells.
Dermal and epidermal homeostasis is compromised in
aging and a variety of disease processes. Aged skin is
characterized as dry, atrophic, inelastic, and wrinkled. The
key molecule required for water retention within skin is HA.
Both the amounts and organization of HA change in skin
with intrinsic (chronological) and extrinsic (photodamage)
aging [4, 89, 90]. With chronological aging while HA is
retained within the aged dermis, it is precipitously lost from
the epidermis. HA retained within the aged dermis is however
modified in its organization and this change together with
epidermal loss are thought to contribute to some of the above
malfunctions of aged skin [4]. Additionally, expression of
skin HA receptors including CD44 are increasingly reduced
with age. Even though intrinsic and extrinsic skin aging
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Figure 5: HA-PE increases epidermal thickness. There is a significant increase in epidermal thickness (𝜇m) of mice treated daily with HA-PE
for 1, 5, and 10 days compared with control groups (HA and Vehicle cream) (mean ± S.E.M, 5 mice per group) (∗ 𝑃 < 0.05, ∗∗ 𝑃 < 0.001). A
single representative H&E section from each of a day 10 HA-PE, HA, and Vehicle Cream mouse is shown, arrows indicate epidermal thickness.

are distinctive processes, they share similarities in molecular
mechanisms. For example, extrinsic causes of premature
aging such as chronic exposure to UV also results in loss of
skin moisture, HA and HA receptor expression. Importantly,
photoaging is also associated with a decrease in the size of
HA that will likely affect its ability to organize into structures
such as pericellular coats [72]. HA performs a variety of
functions in skin and this age dependent loss is considered
to impact upon skin moisture, barrier functions, epidermal
thinning, and sluggish response to injury [34]. The ability
of HA-PE polymers to increase rodent epidermal thickness
and epidermal proliferation predict that this formulation has
the potential for reversing some of the intrinsic and extrinsic
age-related epidermal defects such as epidermal thinning and
reduced repair response [91–93].
Our results showing that HA-PE promotes epidermal
thickening and keratinocyte proliferation are similar to the
ability of exogenous high molecular weight HA to affect
functions of aged keratinocytes in culture and in vivo [33,
35, 39, 42] although in the present study topical HA-PE had
a significantly greater effect than unmodified HA. Our data
suggest that this results from increased basal keratinocyte
proliferation rather than enhanced differentiation. Previous
reports have similarly noted an increase in keratinocyte
proliferation in response to topical HA but noted this effect

was maximal for intermediate (50,000–400,000 Daltons) and
no effect was noted for large HA (>400,000 Daltons) [39].
In another study, topical application of large HA promoted
epidermal barrier function and keratinocyte differentiation
[42]. The different effects of high versus intermediate HA
fragments in these studies may have been due to the documented poor penetration of high molecular weight HA [69]
that is confirmed here. The ability of 500,000 dalton HAPE to promote keratinocyte proliferation is likely because it
efficiently penetrated to and was retained in the basal keratinocyte layer to a much greater extent than unmodified HA.
A number of topical HA formulations have been developed in the past decade most of which are composed of
intermediate-small HA fragments (e.g., <50,000 daltons) or
nanoparticulate formulations [4, 94]. Although these have
shown efficacy (e.g., [95]) in terms of treating skin disorders,
we pose that HA-PE formulations will be more effective
since they are designed to replace the naturally occurring
HA pericellular coat that is depleted during aging and other
conditions that cause epidermal atrophy [35, 39] and will also
therefore be retained within the epidermis for longer times.
Particulate formulations by their nature tend to stimulate
endocytosis and such formulations are rapidly depleted from
tissues [96–98]. Topical application of intermediate unmodified HA has the advantage of being nonparticulate and able
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Figure 9: HA-PE cream does not elicit a local or systemic inflammatory response. The TNF𝛼 expression as a percentage of a wounded mouse
control for day 10 treated mice with HA-PE, HA, or Vehicle Cream using an ELISA (mean ± S.E.M, 5 mice per group). (a) The serum CRP
concentration (ng/mL) of day 10 treated mice with HA-PE, HA, and Vehicle Cream using an ELISA (mean ± S.E.M, 5 mice per group) (b).

to penetrate skin readily but is dependent upon the expression of keratinocyte CD44 for effects on keratinocyte function, which is depleted with age-related or other causes of
epidermal atrophy.
The consequences of exogenous HA or inhibition of endogenous HA show that CD44 mediates the consequences of
HA on keratinocyte function [4, 6, 60, 99]. For example, the
effects of topical HA on keratinocyte differentiation and proliferation are ablated when CD44 function is blocked or
expression is lost [35, 39, 42]. CD44 appears to regulate multiple downstream signaling pathways to control these keratinocyte processes and these include coordination of signaling through EGFR, activation of RHO GTPase and translocation of activated ERK1,2 to the cell nucleus [4, 17, 35, 99, 100].
The mechanisms by which HA-PE control basal keratinocyte
proliferation and the dependence of this effect on CD44
expression are currently being investigated.
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